157 related articles for article (PubMed ID: 38253313)
1. Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference.
Choi MJ; Yu YJ; Kim JW; Ju HJ; Shin SY; Yang YJ; Cheong HJ; Kim WJ; Kim C; Kim HJ; Yoon SK; Park SJ; Gwak W; Lee JW; Kim B; Song JY
Clin Microbiol Infect; 2024 May; 30(5):653-659. PubMed ID: 38253313
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
Bennett C; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; McCallum Pardey TG; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM;
Lancet Infect Dis; 2024 Jun; 24(6):581-593. PubMed ID: 38460525
[TBL] [Abstract][Full Text] [Related]
3. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R;
Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789
[TBL] [Abstract][Full Text] [Related]
4. An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.
Saraf A; Gurjar R; Kaviraj S; Kulkarni A; Kumar D; Kulkarni R; Virkar R; Krishnan J; Yadav A; Baranwal E; Singh A; Raghuwanshi A; Agarwal P; Savergave L; Singh S;
Nat Med; 2024 May; 30(5):1363-1372. PubMed ID: 38637636
[TBL] [Abstract][Full Text] [Related]
5. The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.
Zhou C; Qiu Y; Wang J; Zhong X; Zhu X; Huang X; Yang L; Ji Q; Zhou F; Wu S; Yang M; Zhang J; Liu K; Ji L; Yang H; Li C; Zhao Y
Emerg Microbes Infect; 2024 Dec; 13(1):2320913. PubMed ID: 38860446
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
[TBL] [Abstract][Full Text] [Related]
7. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM; Tan NH; Rietdijk WJR; Geers D; Sablerolles RSG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Rugebregt S; Goorhuis A; Postma DF; Visser LG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; Haagmans BL; van Baarle D; Koopmans MPG; ; van der Kuy PHM; GeurtsvanKessel CH; de Vries RD
Nat Commun; 2024 May; 15(1):4224. PubMed ID: 38762522
[TBL] [Abstract][Full Text] [Related]
8. Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose.
Roozen GVT; Prins MLM; Prins C; Janse JJ; de Gruyter HLM; Pothast CR; Huisman W; Koopman JPR; Lamers OAC; Kuijer M; Myeni SK; van Binnendijk RS; Hartog GD; Heemskerk MHM; Jochems SP; Feltkamp MCW; Kikkert M; Rosendaal FR; Roestenberg M; Visser LG; Roukens AHE
Clin Microbiol Infect; 2024 Jul; 30(7):930-936. PubMed ID: 38552793
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.
Sieghart D; Hana CA; Dürrschmid C; Heinz LX; Haslacher H; Zlesak M; Piccini G; Manenti A; Montomoli E; Jorda A; Fedrizzi C; Hasenoehrl T; Zdravkovic A; Anderle K; Wiedermann U; Drapalik S; Steinbrecher H; Bergmann F; Firbas C; Jordakieva G; Wagner B; Leonardi M; Pierleoni G; Ballini M; Benincasa L; Marchi S; Trombetta C; Perkmann T; Crevenna R; Zeitlinger M; Bonelli M; Aletaha D; Radner H
J Clin Virol; 2024 Aug; 173():105661. PubMed ID: 38503118
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults.
Hu H; Ma F; Gong L; Wang Y; Xu M; Sun H; Hu Q; Wang P; Han L; Xie H
Vaccine; 2024 May; 42(15):3522-3528. PubMed ID: 38704251
[TBL] [Abstract][Full Text] [Related]
11. No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.
Naficy A; Kuxhausen A; Seifert H; Hastie A; Leav B; Miller J; Anteyi K; Mwakingwe-Omari A
Hum Vaccin Immunother; 2024 Dec; 20(1):2327736. PubMed ID: 38513689
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.
Kawashiro K; Suzuki R; Nogimori T; Tsujino S; Iwahara N; Hirose T; Okada K; Yamamoto T; Fukuhara T; Hotta K; Shinohara N
Sci Rep; 2024 May; 14(1):12176. PubMed ID: 38806644
[TBL] [Abstract][Full Text] [Related]
13. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
[TBL] [Abstract][Full Text] [Related]
15. Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responses.
Pattinson D; Jester P; Gu C; Guan L; Armbrust T; Petrie JG; King JP; Nguyen HQ; Belongia EA; Halfmann P; Neumann G; Kawaoka Y
EBioMedicine; 2024 May; 103():105103. PubMed ID: 38574407
[TBL] [Abstract][Full Text] [Related]
16. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
18. Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study.
Liu HH; Xie Y; Yang BP; Wen HY; Yang PH; Lu JE; Liu Y; Chen X; Qu MM; Zhang Y; Hong WG; Li YG; Fu J; Wang FS
Signal Transduct Target Ther; 2024 May; 9(1):129. PubMed ID: 38740763
[TBL] [Abstract][Full Text] [Related]
19. Safety, immunogenicity, and protective effective of inhaled COVID-19 vaccines: A systematic review and meta-analysis.
Song G; Li R; Cheng MQ
J Med Virol; 2024 Apr; 96(4):e29625. PubMed ID: 38650361
[TBL] [Abstract][Full Text] [Related]
20. A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
Iwata S; Pollard AJ; Tada Y; Omoto S; Shibata RY; Igarashi K; Hasegawa T; Ariyasu M; Sonoyama T
Sci Rep; 2024 Apr; 14(1):9830. PubMed ID: 38684712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
